NCT06860282View on ClinicalTrials.gov

A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

December 26, 2022

Primary Completion Date

March 27, 2023

Study Completion Date

March 27, 2023

Conditions
COVID-19Coronavirus Pneumonia
Interventions
DRUG

Remdesivir

Intravenous remdesivir 100 mg

DRUG

CX2101A

CX2101A enteric-coated tablet

DRUG

Placebo

CX2101A placebo enteric-coated tablet

Trial Locations (1)

311202

Zhejiang Xiaoshan Hospital, Hangzhou

Sponsors
All Listed Sponsors
lead

Heronova Pharmaceuticals

INDUSTRY